Head-To-Head Review: Entera Bio (NASDAQ:ENTX) vs. SQZ Biotechnologies (NYSE:SQZ)

Entera Bio (NASDAQ:ENTXGet Free Report) and SQZ Biotechnologies (NYSE:SQZGet Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Institutional & Insider Ownership

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 38.5% of SQZ Biotechnologies shares are owned by institutional investors. 8.9% of Entera Bio shares are owned by company insiders. Comparatively, 16.0% of SQZ Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Entera Bio and SQZ Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Entera Bio N/A -103.40% -85.00%
SQZ Biotechnologies -369.96% -119.83% -59.90%

Valuation and Earnings

This table compares Entera Bio and SQZ Biotechnologies’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio $130,000.00 555.97 -$8.89 million ($0.28) -7.21
SQZ Biotechnologies $18.16 million 0.71 -$79.46 million ($2.61) -0.17

Entera Bio has higher earnings, but lower revenue than SQZ Biotechnologies. Entera Bio is trading at a lower price-to-earnings ratio than SQZ Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Entera Bio and SQZ Biotechnologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio 0 0 1 0 3.00
SQZ Biotechnologies 0 0 0 0 N/A

Entera Bio presently has a consensus target price of $10.00, indicating a potential upside of 395.05%. Given Entera Bio’s higher probable upside, equities research analysts clearly believe Entera Bio is more favorable than SQZ Biotechnologies.

Volatility and Risk

Entera Bio has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500. Comparatively, SQZ Biotechnologies has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500.

Summary

Entera Bio beats SQZ Biotechnologies on 7 of the 13 factors compared between the two stocks.

About Entera Bio

(Get Free Report)

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

About SQZ Biotechnologies

(Get Free Report)

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.